Clinical Trials Browser

Phase 1/2 × INDUSTRY × revumenib × Clear all

NCT04065399 2026-03-18

AUGMENT-101

Phase 1/2 Recruiting

447 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05731947 2026-01-29

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms